Research dossier
Sermorelin — dossier on the GHRH (1-29) fragment
The first 29 amino acids of human GHRH: the shortest fully active fragment, and the starting point of the whole analogue family.
Translated from the French original, which remains the reference version: lire en français →
Sermorelin — also called GRF (1-29) — is the synthetic form of the first 29 amino acids of human GHRH, the hypothalamic hormone that commands the release of growth hormone. It was characterised in the 1980s, after the discovery that this fragment retained the full activity of the hormone.
This dossier describes its identity, its studied mechanism, its regulatory history and its analytical parameters. It contains no information on use.
Molecular identity
| Parameter | Value |
|---|---|
| CAS number | 86168-78-7 |
| Molar mass | 3357.9 g/mol |
| Molecular formula | C₁₄₉H₂₄₆N₄₄O₄₂S |
| Sequence / nature | GHRH humaine (1-29)-NH₂ |
| Purity | ≥99% |
| Appearance | White lyophilised powder |
The values above are those of the product page. The sulfur in the formula comes from the methionine at position 27.
Studied mechanism: the GHRH-R receptor
Sermorelin binds to the GHRH receptor (GHRH-R) of the somatotroph cells of the pituitary. That binding stimulates the synthesis and release of growth hormone through the cyclic AMP pathway.
This pathway is distinct from that of the GHRPs such as GHRP-2 or Ipamorelin, which act at the ghrelin receptor (GHS-R1a). Secretion remains subject to feedback control by somatostatin.
A half-life of a few minutes
Unmodified, sermorelin is rapidly degraded. Dipeptidyl peptidase 4 (DPP-4) cuts it between tyrosine 1 and alanine 2, which inactivates it. Its circulating half-life is described at around 10 to 20 minutes.
This fragility explains the existence of the analogues derived from it:
- CJC-1295 without DAC, which introduces four protective substitutions;
- CJC-1295 with DAC, which additionally adds a bond to albumin;
- tesamorelin, which starts again from the complete GHRH and protects its N-terminal end.
Histoire réglementaire
Sermorelin was authorised in the United States in 1997 under the name Geref, marketed by Serono. It was indicated for the diagnosis of growth hormone deficiency and for the treatment of growth retardation in children linked to that deficiency.
The manufacturer withdrew it from the market in 2008. In a notice published in 2013, the FDA confirmed that this withdrawal was commercial and not related to safety or efficacy. Sermorelin is not authorised as a medicine in France. It appears in section S2 of the World Anti-Doping Agency prohibited list. See our article on the legal framework for peptides in France.
Placing sermorelin among the GHRH analogues
| Critère | Sermorelin | CJC-1295 without DAC | Tesamorelin |
|---|---|---|---|
| Length | 29 amino acids | 29 amino acids | 44 amino acids |
| Modifications | None | 4 substitutions | N-terminal hexenoyl group |
| Molecular mass | 3357.9 g/mol | 3367.97 g/mol | 5135.86 g/mol |
| Status | Withdrawn from the US market in 2008 | No authorisation | Medicine authorised in the United States |
Methodological limits
The clinical literature on sermorelin dates for the most part from the 1980s and 1990s. It deals chiefly with children and with diagnosis. Recent studies are rare.
Analytical parameters
Sermorelin and CJC-1295 without DAC differ by only about 10 daltons (3357.9 against 3367.97 g/mol), despite their four substitutions. Two of them each add 14 Da (Asn→Gln, Gly→Ala), one removes 18 (Met→Leu), and the change to D-alanine does not alter the mass.
That gap is still resolved by a correctly calibrated mass spectrometer. It does, however, require the measured mass to be read precisely: a 10 Da discrepancy is not a tolerance, it is a different molecule. The methionine 27 of sermorelin is also sensitive to oxidation, which adds 16 Da.
Lot verification
The Janoshik certificates of analysis for the catalogue are collected in the lot report register, where each report is tied to the strength and the lot it analyses.
Frequently asked questions
Do sermorelin and GRF (1-29) designate the same compound?
Yes. Sermorelin is the international nonproprietary name, and GRF (1-29) is the description of its sequence: the first 29 amino acids of GHRH.
What is the difference between sermorelin and CJC-1295?
CJC-1295 without DAC is a sermorelin carrying four substitutions that protect it from degradation. The DAC version adds a bond to albumin.
Is sermorelin a medicine?
It was one in the United States under the name Geref, from 1997 to 2008, before a commercial withdrawal. It is not authorised in France.
Why is sermorelin degraded so quickly?
DPP-4 cuts the bond between its first two amino acids. The described half-life is on the order of 10 to 20 minutes.
Further reading: CJC-1295 with DAC: the dossier · CJC-1295, Ipamorelin, GHRP-6: GHRH and GHRP compared
Dossiers in the same category
- CJC-1295 without DAC — CAS 863288-34-0
- CJC-1295 with DAC — CAS 446262-90-4
- Tesamorelin — CAS 218949-48-5
References
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006. PubMed
- Steiger A, et al. Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology. 1992. PubMed